



Contact:

**Nancy F. Morter**

Dilon Technologies Inc.

**C: 757-589-3914**

O: 757-269-4910 x 302

E: [nfmorter@dilon.com](mailto:nfmorter@dilon.com)

[www.dilon.com](http://www.dilon.com)

### **Dilon Technologies Secures Major Financial Deal Will Support Increase in Product Demand and Company Growth**

*(Newport News, VA - August 8, 2006)* Dilon Technologies, LLC - a U.S. manufacturer and supplier of high-resolution molecular imaging systems recently completed an equity offering of 7.25 million dollars that will propel the company's sales to new heights. The deal was placed by Taglich Brothers, Inc. of New York, NY- a full-service investment banking firm focused exclusively on microcap companies. Michael Taglich, President of Taglich Brothers, commented that "Based on the spectacular clinical results that the Dilon 6800 Gamma Camera has shown in detecting breast cancer, we are convinced that it should be regarded as an integral part of the standard of care for breast cancer detection and preoperative planning. We are excited about providing the necessary capital to spread the word about the gamma camera, and are impressed by the growing momentum of sales. Most importantly, we believe accelerating the marketing of the 6800 will save many lives."

"The capital infusion provides funding for the advancement of our national sales operations and international business ventures" said Lon Slane, President of Dilon Technologies. Having only marketed its medical imaging product for two years, Dilon has successfully sold gamma cameras- optimized for breast cancer diagnosis- across the US and into Europe; with installations pending in Canada and Israel. Such wide acceptance of the product's place in breast cancer diagnostics requires this additional funding to support demand and the company's growth.

Breast-Specific Gamma Imaging (BSGI) is the novel imaging technique enabled by Dilon's dedicated camera. This diagnostic test provides a functional imaging component to breast cancer detection not found in other types of breast imaging: such as mammography, ultrasound and MRI. For this procedure a patient receives a small dose of a radiopharmaceutical (a tracing agent) which is absorbed by all the cells of the body. However, because cancer cells have a higher rate of metabolic activity they absorb up to nine times more of the agent, and in turn are revealed as high intensity focal points, or "hot spots" that indicate cancer.



BSGI is an ideal complementary diagnostic procedure to mammography- which is still considered the primary screening tool for breast cancer. But as with any test, mammography does have its diagnostic limitations; and for patients who have any number of risk factors additional testing is generally required. Some of these risk factors that make accurate interpretation of mammograms challenging include patients who present with: dense breast tissue, suspicious areas on a mammogram, lumps that can be felt but not seen with mammography or ultrasound, implants and breast augmentation, scarring from previous surgeries, women on hormone replacement therapy and those with a strong positive family history of breast cancer.

BSGI with the Dilon 6800 is rapidly changing the diagnostic protocol for breast cancer detection for radiologists and surgeons alike. For surgeons, this test helps confirm the extent of disease for patients with known cancer- providing valuable information for pre-surgical planning. While Dilon's compact and mobile system is niched in breast imaging, and primarily serves as an adjunctive procedure to mammography, additional applications for this high-resolution technology include the parathyroid and pediatrics - as well as other body parts small enough to fit within the 6x8 inch field of view.

### **About Dilon**

Dilon Technologies, LLC, is bringing innovative new medical products to the market based on research conducted at leading national research laboratories. Dilon's cornerstone product is the Dilon 6800 Gamma Camera to perform BSGI, a molecular medicine procedure that images the metabolic activity of breast lesions through radiotracer uptake, using a high-resolution, anatomic-specific gamma camera. Several leading medial centers around the country are now offering BSGI to their patients, including: Beth Israel Medical Center, New York; George Washington Medical Center, Washington, D.C.; Alexian Brothers Medical Center, Chicago; Breast Health Institute, Orlando; and West Valley Imaging, Las Vegas. For more information on Dilon visit [www.dilon.com](http://www.dilon.com).

###